VivoSim Labs, INC.
About VivoSim Labs, INC.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $144.0K
- Net income
- -$2.5M
- Total assets
- $14.7M
- Market cap
- $3.5M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $3.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 16, 2011
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review VivoSim Labs, INC..